Argenica Therapeutics Limited (ASX:AGN)

Argenica Therapeutics Income Statement

Financials in millions AUD. Fiscal year is July - June.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 31, 2025	Jun 30, 2025	Jun 30, 2024	Jun 30, 2023	Jun 30, 2022	Jun 30, 2021
Other Revenue	1.01	3.21	2.6	1.75	0.26	0.3
Revenue	1.01	3.21	2.6	1.75	0.26	0.3
Revenue Growth (YoY)	-67.31%	23.70%	48.46%	575.38%	-12.49%	-
Gross Profit	1.01	3.21	2.6	1.75	0.26	0.3
Selling, General & Admin	2.84	2.65	2.11	1.86	1.43	0.64
Research & Development	8.25	8.13	6.02	4.31	2.5	0.42
Operating Expenses	11.14	10.9	8.27	6.62	4.35	1.33
Operating Income	-10.13	-7.68	-5.67	-4.87	-4.09	-1.03
Interest Expense	-0	-0	-0	-0	-0	-0
Interest & Investment Income	0.33	0.51	0.19	0.06	0	0
Pretax Income	-9.8	-7.17	-5.48	-4.82	-4.09	-1.03
Income Tax Expense	-	-	-	-	-	0
Net Income	-9.8	-7.17	-5.48	-4.82	-4.09	-1.03
Net Income to Common	-9.8	-7.17	-5.48	-4.82	-4.09	-1.03
Shares Outstanding (Basic)	129	128	104	74	74	35
Shares Outstanding (Diluted)	129	128	104	74	74	35
Shares Change (YoY)	9.73%	22.97%	40.29%	-	108.80%	112.54%
EPS (Basic)	-0.08	-0.06	-0.05	-0.07	-0.06	-0.03
EPS (Diluted)	-0.08	-0.06	-0.05	-0.07	-0.06	-0.03
Gross Margin	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%
Operating Margin	-1006.58%	-239.05%	-218.30%	-278.59%	-1579.49%	-347.76%
Profit Margin	-973.56%	-223.12%	-210.92%	-275.16%	-1578.84%	-347.72%
EBIT	-10.13	-7.68	-5.67	-4.87	-4.09	-1.03
EBIT Margin	-	-239.05%	-218.30%	-278.59%	-	-
Revenue as Reported	1.34	3.73	2.79	1.81	0.26	0.3

Source: S&P Global Market Intelligence. Standard template. Financial Sources.